JPMorgan CEO Predicts DoubleDigit Growth in Investment Banking Fees for Second Quarter Indian Markets Edge Higher on RBI Support But Weak Momentum Caps Gains Voya Financial Reports Earnings Growth Across All Business Segments JhunjhunwalaPartnered Fund Acquires Stake in Tourism Finance Corporation of India Management Discusses Outlook AI Economy Reshapes Workforce BlueCollar Skilled Trades Gain as WhiteCollar Entry Jobs Slow Sebis Digital Bonds Initiative May Deepen Indias Debt Market Benefiting Retail Investors Most PYXS Q1 2026 Earnings BetterthanExpected Loss Highlights Progress in Oncology Pipeline NHC Q1 2023 Earnings EPS of 079 Reported Amidst Flat Stock Performance DUK Q1 2026 Earnings Beats Estimates with Resilient Regulated Operations DTW Q1 2026 Earnings EPS Misses Estimates as Debenture Price Slips Everus Construction Group ECG Q1 2026 Earnings Strong EPS Beat Drives Investor Caution VUZI Q1 2026 Earnings EPS Beat and Narrowed Loss Boost Investor Sentiment Spruce Biosciences SPRB Edges Higher Testing Key Resistance Near 5440 Deckers Outdoor DECK Rallies 395 to 10667 Holds Above Key Support Ebang International Holdings EBON Gains 245 as Shares Test Key Resistance Level Rio Tinto Surges 238 Testing Resistance at 11205 Amid Strong Momentum AutoZone AZO Plunges Over 10 Key Support and Resistance Levels in Focus AI Talent Arms Race Tech Giants Pay Millions in Salaries Billions in Equity to Secure Top Researchers ARLP Q1 2026 Earnings Modest EPS Beat Amid Flat Revenue Disclosure Antero Midstream Corporation AM Gains 165 as Energy Sector Momentum Continues UL Q4 2010 Earnings EPS Beat Amidst Sluggish TopLine Signals BRAG Q1 2026 Earnings EPS Surpasses Estimates Amid Prudent Cost Controls BMY Q1 2026 Earnings EPS Beat on Cost Discipline and Operational Execution EOSE Q1 2026 Earnings EPS Beats Estimates by 188 as Stock Surges Research Solutions Inc RSSS Q1 2026 Earnings EPS Falls Short as Shares Edge Higher HOMB Q1 2026 Earnings EPS Slightly Misses Estimate Shares Modestly Higher STOK Q1 2026 Earnings EPS Surprises to the Upside as Clinical Pipeline Advances